Patient acceptability of circulating tumour DNA testing in endometrial cancer follow-up.
cancer recurrence
circulating tumour DNA
endometrial cancer
monitoring
patient acceptability
Journal
European journal of cancer care
ISSN: 1365-2354
Titre abrégé: Eur J Cancer Care (Engl)
Pays: England
ID NLM: 9301979
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
revised:
15
10
2020
received:
03
08
2020
accepted:
11
01
2021
pubmed:
23
2
2021
medline:
30
9
2021
entrez:
22
2
2021
Statut:
ppublish
Résumé
Circulating tumour DNA (ctDNA) is emerging as a potential option to detect disease recurrence in many cancer types, however, ensuring patient acceptability of changing clinical practice and the introduction of new technology is paramount. Patients enrolled in a non-intervention cohort study determining the ability of ctDNA to detect recurrent endometrial cancer (EC) were invited to participate in a semi-structured interview. Analysis was performed by Template Analysis. Eighteen patients were interviewed. A ctDNA blood test was viewed by participants as more physically and psychologically acceptable than clinical examination to monitor for EC recurrence. In particular, participants expressed overwhelming preference for a blood test rather than pelvic examination. Although participants acknowledged that an abnormal ctDNA result could cause anxiety, they expressed a preference to be informed of their results, even if a recurrence was too small to detect radiologically. Explanations for these opinions were a desire for certainty whether their cancer would recur or not, and knowledge would help them be more aware of symptoms that should be reported to their clinician. ctDNA monitoring to identify EC recurrence appears to be acceptable to patients, and for many, it may be preferable to clinical examination.
Substances chimiques
Biomarkers, Tumor
0
Circulating Tumor DNA
0
Types de publication
Journal Article
Langues
eng
Pagination
e13429Subventions
Organisme : Hope Against Cancer
ID : RM60GO754
Organisme : Hope Against Cancer/Leicester Precision Medicine Institute in conjunction withUK Department of Health on an Experimental Cancer Medicine Centre
ID : C10604/A25151
Organisme : Medical Research Council
ID : MCPC17194
Pays : United Kingdom
Informations de copyright
© 2021 The Authors. European Journal of Cancer Care published by John Wiley & Sons Ltd.
Références
Andre, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., Yamashita, T., Lu, Y. S., Inoue, K., Takahashi, M., Papai, Z., Longin, A. S., Mills, D., Wilke, C., Hirawat, S., & … Group S.-S (2019). Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. New England Journal of Medicine, 380, 1929-1940.
Aujoulat, I., Luminet, O., & Deccache, A. (2007). The perspective of patients on their experience of powerlessness. Qualitative Health Research, 17, 772-785.
Aung, L., Howells, R. E., Lim, K. C., Hudson, E., & Jones, P. W. (2014). Why routine clinical follow-up for patients with early stage endometrial cancer is not always necessary: a study on women in South Wales. International Journal of Gynecological Cancer, 24, 556-563.
Beaver, K., Williamson, S., Sutton, C., Hollingworth, W., Gardner, A., Allton, B., Abdel-Aty, M., Blackwood, K., Burns, S., Curwen, D., Ghani, R., Keating, P., Murray, S., Tomlinson, A., Walker, B., Willett, M., Wood, N., & Martin-Hirsch, P. (2017). Comparing hospital and telephone follow-up for patients treated for stage-I endometrial cancer (ENDCAT trial): A randomised, multicentre, non-inferiority trial. BJOG, 124, 150-160.
Bhaskar, R. (1989). Reclaiming reality: A critical introduction to contemporary philosophy. Verso.
Braun, V., & Clarke, V. (2006). Using thematic analysis in psychology. Qualitative Research in Psychology, 3, 77-101.
Brooks, J., & King, N. (2014). Doing template analysis: Evaluating an end-of-life care service. SAGE Research Methods Cases. https://doi.org/10.4135/978144627305013512755.
Brown, L., Payne, S., & Royle, G. (2002). Patient initiated follow up of breast cancer. Psychooncology, 11, 346-355.
Coleman, L., & Newton, C. (2020). Patient initiated follow up after gynaecological malignancy: National survey of current UK practice. European Journal of Obstetrics & Gynecology and Reproductive Biology, 248, 193-197.
Colombo, N., Preti, E., Landoni, F., Carinelli, S., Colombo, A., Marini, C., & Sessa, C.; Group E. G. W (2013). Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 24, vi33-vi38.
Coombes, R. C., Page, K., Salari, R., Hastings, R. K., Armstrong, A., Ahmed, S., Ali, S., Cleator, S., Kenny, L., Stebbing, J., Rutherford, M., Sethi, H., Boydell, A., Swenerton, R., Fernandez-Garcia, D., Gleason, K. L. T., Goddard, K., Guttery, D. S., Assaf, Z. J., … Shaw, J. A. (2019). Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence. Clinical Cancer Research, 25, 4255-4263.
Crist, J. V., & Grunfeld, E. A. (2013). Factors reported to influence fear of recurrence in cancer patients: A systematic review. Psychooncology, 22, 978-986.
Cross, M. J., March, L. M., Lapsley, H. M., Byrne, E., & Brooks, P. M. (2006). Patient self-efficacy and health locus of control: relationships with health status and arthritis-related expenditure. Rheumatology (Oxford), 45, 92-96.
De Boer, S. M., Powell, M. E., Mileshkin, L., Katsaros, D., Bessette, P., Haie-Meder, C., Ottevanger, P. B., Ledermann, J. A., Khaw, P., D'amico R., Fyles, A., Baron, M. H., Jurgenliemk-Schulz, I. M., Kitchener, H. C., Nijman, H. W., Wilson, G., Brooks, S., Gribaudo, S., Provencher, D., … Group P. S. (2019) Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncology, 19(3), 295-309.
Fletcher, A. J. (2017). Applying critical realism in qualitative research: Methodology meets method. International Journal of Social Research Methodology, 20(2), 181-194. https://doi.org/10.1080/13645579.2016.1144401.
Foundationone. https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019S006C.pdf.
Frankland, J., Brodie, H., Cooke, D., Foster, C., Foster, R., Gage, H., Jordan, J., Mesa-Eguiagaray, I., Pickering, R., & Richardson, A. (2019). Follow-up care after treatment for prostate cancer: evaluation of a supported self-management and remote surveillance programme. BMC Cancer, 19, 368.
Gadducci, A., Cosio, S., Fanucchi, A., Cristofani, R., & Genazzani, A. R. (2000). An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer. Anticancer Research, 20, 1977-1984.
Garcia-Murillas, I., Chopra, N., Comino-Mendez, I., Beaney, M., Tovey, H., Cutts, R. J., Swift, C., Kriplani, D., Afentakis, M., Hrebien, S., Walsh-Crestani, G., Barry, P., Johnston, S. R. D., Ring, A., Bliss, J., Russell, S., Evans, A., Skene, A., Wheatley, D., … Turner, N. C. (2019). Assessment of molecular relapse detection in early-stage breast cancer. JAMA Oncology, 5(10), 1473-1478.
Guardant360. https://www.fda.gov/medical-devices/recently-approved-devices/Guardant360-cdx-p200010.
Heeke, S., Benzaquen, J., Hofman, V., Ilie, M., Allegra, M., Long-Mira, E., Lassalle, S., Tanga, V., Salacroup, C., Bonnetaud, C., Fayada, J., Gazoppi, L., Ribeyre, L., Castelnau, O., Garnier, G., Cattet, F., Nanni, I., De Fraipont, F., Cohen, C., … Hofman, P. (2020). Critical Assessment in Routine Clinical Practice of Liquid Biopsy for EGFR Status Testing in Non-Small-Cell Lung Cancer: A Single-Laboratory Experience (LPCE, Nice, France). Clinical Lung Cancer, 21(56-65), e58.
Ignatov, T., Eggemann, H., Costa, S. D., Ortmann, O., & Ignatov, A. (2018). Endometrial cancer subtypes are associated with different patterns of recurrence. Journal of Cancer Research and Clinical Oncology, 144, 2011-2017.
Jeppesen, M. M., Jensen, P. T., Hansen, D. G., Christensen, R. D., & Mogensen, O. (2018). Patient-initiated follow up affects fear of recurrence and healthcare use: a randomised trial in early-stage endometrial cancer. BJOG, 125, 1705-1714.
King, N. (2004). Using templates in thematic analysis of text. Sage.
Kumarakulasingam, P., Mcdermott, H., Patel, N., Boutler, L., Tincello, D. G., Peel, D., & Moss, E. L. (2019). Acceptability and utilisation of patient-initiated follow-up for endometrial cancer amongst women from diverse ethnic and social backgrounds: A mixed methods study. European Journal of Cancer Care, 28, e12997.
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., Wong, F., Azad, N. S., Rucki, A. A., Laheru, D., Donehower, R., Zaheer, A., Fisher, G. A., Crocenzi, T. S., Lee, J. J., … Diaz, L. A. (2017). Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science, 357, 409-413.
Luqman, I., Wickham-Joseph, R., Cooper, N., Boulter, L., Patel, N., Kumarakulasingam, P., & Moss, E. (2020). Patient-initiated follow-up for low risk endometrial cancer: A cost-analysis evaluation. International Journal of Gynecological Cancer, 30(7), 1000-1004.
Miller, K. D., Siegel, R. L., Lin, C. C., Mariotto, A. B., Kramer, J. L., Rowland, J. H., Stein, K. D., Alteri, R., & Jemal, A. (2016). Cancer treatment and survivorship statistics, 2016. CA: A Cancer Journal for Clinicians, 66, 271-289.
Moss, E. L., Gorsia, D. N., Collins, A., Sandhu, P., Foreman, N., Gore, A., Wood, J., Kent, C., Silcock, L., & Guttery, D. S. (2020). Utility of circulating tumor DNA for detection and monitoring of endometrial cancer recurrence and progression. Cancers (Basel), 12(8), 2231.
Nowell, L., Norris, L., White, D., & Moules, D. (2017). Thematic analysis. International Journal of Qualitative Methods, 16, 160940691773384.
Pereira, E., Camacho-Vanegas, O., Anand, S., Sebra, R., Catalina, C. S., Garnar-Wortzel, L., Nair, N., Moshier, E., Wooten, M., Uzilov, A., Chen, R., Prasad-Hayes, M., Zakashansky, K., Beddoe, A. M., Schadt, E., Dottino, P., & Martignetti, J. A. (2015). Personalized circulating tumor DNA biomarkers dynamically predict treatment response and survival in gynecologic cancers. PLoS One, 10, e0145754.
Simard, S., Savard, J., & Ivers, H. (2010). Fear of cancer recurrence: specific profiles and nature of intrusive thoughts. Journal of Cancer Survivorship, 4, 361-371.
Sundar, S., Balega, J., Crosbie, E., Drake, A., Edmondson, R., Fotopoulou, C., Gallos, I., Ganesan, R., Gupta, J., Johnson, N., Kitson, S., Mackintosh, M., Martin-Hirsch, P., Miles, T., Rafii, S., Reed, N., Rolland, P., Singh, K., Sivalingam, V., & Walther, A. (2017). BGCS uterine cancer guidelines: Recommendations for practice. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 213, 71-97.
Wallston, K. A., Wallston, B. S., & Devellis, R. (1978). Development of the Multidimensional Health Locus of Control (MHLC) scales. Health Education Monographs, 6, 160-170.